When Jeremy Levin takes the helm as president and CEO of Teva Pharmaceutical Industries Ltd. in May, he will be taking on the huge task of restoring investor confidence in the company and its growth prospects. Sellside analysts and business media were quick to speculate he would do that by focusing on Teva's fledgling branded drugs business. But Levin made clear to BioCentury that generics and emerging markets will be as important to further developing Teva's global footprint as branded drugs.

"If you are building a global company, you can't take a one-size-fits-all approach. Your approach needs to address regional and local needs and requirements. If you don't, you are dependent on markets in the U.S., EU and Japan," Levin said last week.